Schrodinger, Viva collaborate on structure-based drug discovery

By The Science Advisory Board staff writers

July 28, 2020 -- Schrodinger and Viva Biotech have entered a strategic collaboration to expand structure-based drug discovery by generating de novo crystal structures of high-value targets.

Under the terms of the collaboration, Schrodinger will identify drug discovery targets for which there are currently no crystal structures. Viva Biotech will use x-ray crystallography design to structurally enable the targets by generating high-resolution structures with bound ligands.

Schrodinger will then use its computational platform to explore chemical space with the goal of designing novel therapeutic candidates for the targets.


Copyright © 2020 scienceboard.net
 


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.